Anti-Müllerian hormone: Determination of ovarian reserve in early breast cancer patients

Endocrine-Related Cancer

Volumn 21, Issue 1, 2014, Pages

  Bozza, Claudia ^a   Puglisi, Fabio ^a,b   Lambertini, Matteo ^c   Osa, Etin Osa ^d   Manno, Massimo ^e   Del Mastro, Lucia ^c  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Pordenone Hospital   (Italy)

Author keywords

Breast; Growth factor; Hormone action; Oncology

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GONADORELIN DERIVATIVE; IFOSFAMIDE; MELPHALAN; MUELLERIAN INHIBITING FACTOR; VINBLASTINE; ANTINEOPLASTIC AGENT; ESTRADIOL; FOLLITROPIN; GROWTH FACTOR; INHIBIN; INHIBIN B; TUMOR MARKER;

ASSISTIVE TECHNOLOGY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; EARLY CANCER; FERTILITY; GONADAL DISEASE; HUMAN; INFERTILITY; INFERTILITY THERAPY; MENOPAUSE; OVARIAN RESERVE; REVIEW; BLOOD; BREAST; BREAST TUMOR; FEMALE; HORMONE ACTION; ONCOLOGY; OVARY FOLLICLE; PATHOPHYSIOLOGY;

BREAST; GROWTH FACTOR; HORMONE ACTION; ONCOLOGY;

ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INHIBINS; OVARIAN FOLLICLE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893587462     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0335     Document Type: Review

References (82)

1. Amir E, Seruga B, Freedman O & Clemons M 2009 Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ 339 4261. (doi:10.1136/bmj.b4261)
2. Amir E, Freedman O, Allen L, Colgan T & Clemons M 2010 Defining ovarian failure in amenorrheic young breast cancer patients. Breast 19 545-548. (doi:10.1016/j.breast.2010.06.003)
3. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G et al. 2008 A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Investigation 26 286-295. (doi:10.1080/07357900701829777)
4. Anderson R & Cameron D 2011 Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. Journal of Clinical Endocrinology and Metabolism 96 1336-1343. (doi:10.1210/jc.2010-2582)
5. Anderson RA, Themmen APN, Al-Qahtani A, Groome NP & Cameron DA 2006 The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Human Reproduction 21 2583-2592. (doi:10.1093/humrep/del201)
6. Anderson RA, Nelson SM & Wallace WH 2012 Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 71 28-33. (doi:10.1016/j.maturitas.2011.11.008)
7. Anderson RA, Rosendahl M, Kelsey TW & Cameron DA 2013 Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. European Journal of Cancer 49 3404-3411. (doi:10.1016/j.ejca.2013.07.014)
8. Arbo E, Vetori DV, Jimenez MF, Freitas FM, Lemos N & Cuhna-Filho JS 2007 Serum anti-Müllerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Human Reproduction 22 3192-3196. (doi:10.1093/humrep/ dem258)
9. Bath LE, Wallace WHB, Shaw MP, Fitzpatrick C & Anderson RA 2003 Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Human Reproduction 18 2368-2374. (doi:10.1093/humrep/deg473)
10. vanBeek RD, vanden Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R & de Muinck Keizer-Schrama SM 2007 Anti Müllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. Journal of Clinical Endocrinology and Metabolism 92 3869-3874. (doi:10.1210/jc.2006-2374)
11. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlputz M, Rosenbrock J, Halbsguth T et al. 2013 Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. Journal of Clinical Oncology 31 231-239. (doi:10.1200/JCO.2012.44.3721)
12. Bentzen JG, Forman JL, Pinborg A, Lidegaard Ø, Larsen EC, Friis-Hansen L, Johannsen TH & Nyboe Andersen A 2012 Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reproductive Biomedicine Online 25 612-619. (doi:10.1016/j.rbmo.2012.09.001)
13. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA & Wallace WH 2012 Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and post-pubertal girls treated for cancer: a prospective study. Journal of Clinical Endocrinology and Metabolism 97 2059-2067. (doi:10.1210/jc.2011-3180)
14. Clemons M & Simmons C 2007 Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Research and Treatment 104 115-120. (doi:10.1007/s10549-006-9401-y)
15. Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, Beckmann MW & Strissel P 2007 Correlations between anti-Müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. European Journal of Medical Research 12 604-608.
16. Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G & Raine-Fenning NJ 2012 Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound in Obstetrics & Gynecology 39 574-580. (doi:10.1002/uog.10114)
17. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C & Dewailly D 2010 Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reproductive Biomedicine Online 20 280-285. (doi:10.1016/j.rbmo.2009.11.010)
18. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C et al. 2011 Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. Journal of the American Medical Association 30 269-276. (doi:10.1001/jama.2011. 991)
19. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, Gosiengfiao Y & Gracia CR 2013 Pretreatment anti Müllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertility and Sterility 99 477-483. (doi:10.1016/j.fertnstert.2012.09.039)
20. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA & Themmen AP 1999 Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140 5789-5796. (doi:10.1210/en.140.12.5789)
21. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA et al. 2001 Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142 4891-4899. (doi:10.1210/en.142.11.4891)
22. Ebner T, Sommergruber M, Moser M, Shelb O, Schreier-Lechner E & Tews G 2006 Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Human Reproduction 21 2022-2026. (doi:10.1093/humrep/del127)
23. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN & Abou-Setta AM 2013 Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage. Obstetrics and Gynecology 121 78-86. (doi:10.1097/AOG.0b013e31827374e2)
24. Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R & Taieb J 2007 Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 92 1796-1802. (doi:10.1210/jc.2006-1053)
25. Ganz P & Hahn E 2008 Implementing a survivorship care plan for patients with breast cancer. Journal of Clinical Oncology 26 759-767. (doi:10.1200/JCO.2007.14.2851)
26. Garcia A, Grynnerup A & Sorensen S 2012 The role of anti-Müllerian hormone in female fertility and infertility - an overview. Acta Obstetricia et Gynecologica Scandinavica 91 1252-1260. (doi:10.1111/j.1600- 0412.2012.01471.x)
27. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O et al. 2011 Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. Journal of Clinical Oncology 29 2334-2341. (doi:10.1200/JCO.2010.32.5704)
28. Giraudi S, Marroni P, Boni L, Bighin C, Levaggi A, Bini G, Taveggia P, Venturini M, Pronzato P & Del Mastro L 2009 Anti-Müllerian hormone (AMH) and ovarian function in young breast cancer (BC) women receiving adjuvant chemotherapy (CT). Journal of Clinical Oncology 27 (Suppl) e11544.
29. Gougeon A, Ecochard R & Thalabard JC 1994 Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biology of Reproduction 50 653-663. (doi:10.1095/biolreprod50.3.653)
30. Gracia C & Jeruss JS 2013 Lives in the balance: women with cancer and the right to fertility care. Journal of Clinical Oncology 31 668-669. (doi:10.1200/JCO.2012.47.5798)
31. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A & Ginsberg JP 2012 Impact of cancer therapies on ovarian reserve. Fertility and Sterility 97 134-140. (doi:10.1016/j.fertnstert.2011.10.040)
32. Guerrero A, Gavilà J, Folkerd E, Ortiz B, Martinez F, Garcia A, Climent MA, Guillem V & Ruiz A 2013 Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapyinduced amenorrhea (CIA) who switched from tamoxifen to exemestane. Annals of Oncology 24 674-679. (doi:10.1093/annonc/mds464)
33. Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A & Kieback DG 2012 Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric 15 460-466. (doi:10.3109/13697137.2011.647839)
34. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM & Cohen-Bacrie P 2004 Serum anti Müllerian hormone/Müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility 91 4057-4063.
35. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E & Thun MJ 2003 Cancer statistics, 2003. CA: A Cancer Journal for Clinicians 53 5-26. (doi:10.3322/canjclin.53.1.5)
36. Johnson JA, Tough S & Society of Obstetricians and Gynaecologists of Canada 2012 Delayed child-bearing. Journal of Obstetrics and Gynaecology Canada 34 80-93.
37. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T & Tapanainen JS 2013 Anti Müllerian hormone levels decrease in women using combined contraception independently of administration route. Fertility and Sterility 99 1305-1310. (doi:10.1016/j.fertnstert.2012.11.034)
38. La Marca A, Stabile G, Artenisio AC & Volpe A 2006 Serum anti-Müllerian hormone throughout the human menstrual cycle. Human Reproduction 21 3103-3107. (doi:10.1093/humrep/del291)
39. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G & Volpe A 2010 Anti-Müllerian hormone (AMH)as a predictivemarker in assisted reproductive technology (ART). Human Reproduction Update 16 113-130. (doi:10.1093/humupd/dmp036)
40. Lambertini M, Anserini P, Levaggi A, Poggio F & Del Mastro L 2013 Fertility counseling of young breast cancer patients. Journal of Thoracic Disease 5 S68-S80. (doi:10.3978/j.issn.2072-1439.2013.05.22)
41. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K & Andersen AN 2003a Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH !10 IU/l. Human Reproduction 18 417-422. (doi:10.1093/humrep/deg073)
42. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C & Andersen AN 2003b Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. Journal of Clinical Endocrinology and Metabolism 88 5307-5314. (doi:10.1210/jc.2003-030352)
43. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV & Oktay K 2006 American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. Journal of Clinical Oncology 24 2917-2931. (doi:10.1200/JCO.2006.06.5888)
44. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM & Lee MS 2009 Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reproductive Biology and Endocrinology 7 100. (doi:10.1186/1477-7827-7-100)
45. Lee S, Ozkavukcu N, Heytens E, Moy F, Alappat RM & Oktay K 2011 Anti-Müllerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. Journal of Assisted Reproduction and Genetics 28 651-656. (doi:10.1007/s10815-011-9567-z)
46. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB & Tremellen KP 2007 Anti-Müllerian hormone as a predictor of IVF outcome. Reproductive Biomedicine Online 14 602-610. (doi:10.1016/S1472-6483(10)61053-X)
47. Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman RE, Fallowfield L, McLinden M, Mansi J & Thomas G 2010 The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant adjuvant chemotherapy for early breast cancer. Journal of Clinical Oncology 28 590.
48. Leonard RC, Adamson D, Bertelli G, McLinden M, Haiying N, Dunlop J, Mansi J, Coleman RE, Thomas G & Anderson R 2012 The relative value of anti-Müllerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: results from the OPTION trial. Journal of Clinical Oncology 30 1094.
49. Li HW, Wong CY, Yeung WS, Ho PC & Ng EH 2011 Serum anti-Müllerian hormone level is not altered in women using hormonal contraceptives. Contraception 83 582-585. (doi:10.1016/j.contraception.2010.09. 007)
50. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, de Jong FH, Fauser BJ & Laven JS 2008a Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reproductive Biomedicine Online 16 664-670. (doi:10.1016/S1472-6483(10)60480-4)
51. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P & Laven JS 2008b Anti-Müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Human Reproduction 23 674-678. (doi:10.1093/humrep/dem392)
52. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de Jong FH & van den Heuvel-Eibrink MM 2009 Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Human Reproduction 24 982-990. (doi:10.1093/humrep/den487)
53. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH & Oktay K 2013 Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 31 2500-2510. (doi:10.1200/JCO.2013.49. 2678)
54. Lum SS, Woltering EA, Fletcher WS & Pommier RF 1997 Changes in serum estrogen levels in women during tamoxifen therapy. American Journal of Surgery 173 399-402. (doi:10.1016/S0002-9610(97)00072-X)
55. Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, Groome NP, Davies MC & Chatterjee R 2007 Predictors of ovarian reserve in young women with breast cancer. British Journal of Cancer 96 1808-1816. (doi:10.1038/sj.bjc.6603814)
56. Massagué J 1990 The transforming growth factor-b family. Annual Review of Cell Biology 6 597-641. (doi:10.1146/annurev.cb.06.110190.003121)
57. Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, Primic-Zakelj M, Bruzzi P, Bouchardy C & Fucic A 2012 Breast cancer incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Research and Treatment 134 363-702. (doi:10.1007/s10549-012-2031-7)
58. Oktay K, Kim JY, Barad D & Babayev SN 2010 Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology 28 240-244. (doi:10.1200/JCO.2009.24.2057)
59. Partridge A, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M & Ginsburg E 2010 Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertility and Sterility 94 638-644. (doi:10.1016/j.fertnstert.2009.03.045)
60. Rajpert-DeMeyts E, Jørgensen N, Graem N, Müller J, Cate RL & Skakkebaek NE 1999 Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism 84 3836-3844. (doi:10.1210/jc.84.10.3836)
61. Randolph JF Jr, Crawford S, Dennerstein L, Cain K, Harlow SD, Little R, Mitchell ES, Nan B, Taffe J & Yosef M 2006 The value of folliclestimulating hormone concentration and clinical findings as markers of the late menopausal transition. Journal of Clinical Endocrinology and Metabolism 91 3034-3040. (doi:10.1210/jc.2006-0243)
62. Rodriguez S, Campo-Engelstein L & Emanuel L 2013 Fertile future? Potential social implications of oncofertility Journal of Clinical Oncology 31 665-667. (doi:10.1200/JCO.2012.44.0990)
63. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K & Andersen AN 2010 Dynamics and mechanisms of chemotherapyinduced ovarian follicular depletion in women of fertile age. Fertility and Sterility 94 156-166. (doi:10.1016/j.fertnstert.2009.02.043)
64. Ruddy KJ, Gelber S, Tamimi RM, Ginsburg ES, Schapira L, Come SE, Meyer ME, Winer E & Partridge AH 2012 Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal of Clinical Oncology 30 (Suppl) 9071.
65. Salama M, Winkler K, Murach KF, Seeber B, Ziehr SC & Wildt L 2013 Female fertility loss and preservation: threats and opportunities. Annals of Oncology 24 598-608. (doi:10.1093/annonc/mds514)
66. Seifer DB, Mac Laughlin DT, Christian BP, Feng B & Shelden RM 2002 Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility 77 468-471. (doi:10.1016/S0015-0282(01)03201-0)
67. Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, Brinton LA & Dorgan JF 2011 Serum anti Müllerian hormone in healthy premenopausal women. Fertility and Sterility 95 2718-2721. (doi:10.1016/j. fertnstert.2011.05.051)
68. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL & Blazar AS 2006 Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 21 159-163. (doi:10.1093/humrep/dei270)
69. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM & Braat DD 2007 Anti Müllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertility and Sterility 87 223-226. (doi:10.1016/j.fertnstert.2006. 06.019)
70. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL & Thun M 2006 Trends in breast cancer by race and ethnicity: update 2006. CA: A Cancer Journal for Clinicians 56 168-183. (doi:10.3322/canjclin. 56.3.168)
71. Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ & Hayes D 2006 Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of Clinical Oncology 24 2444-2447. (doi:10.1200/JCO.2005.05.3694)
72. Sowers MR, Eyvazzadeh A, Mc Connell D, Yosef M, Jannausch ML, Zhang D, Harlow S & Randolph JF Jr 2008 Anti-Müllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. Journal of Clinical Endocrinology and Metabolism 93 3478-3483. (doi:10.1210/jc.2008-0567)
73. Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD & Randolph JF 2010 Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertility and Sterility 94 1482-1486. (doi:10.1016/j. fertnstert.2009.07.1674)
74. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P & de Ziegler D 2008 Serum anti Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertility and Sterility 90 395-400. (doi:10.1016/j.fertnstert.2007.06. 023)
75. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR & DeMichele A 2010 Anti Müllerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116 592-599. (doi:10.1002/cncr.24746)
76. Su HI, Flatt SW, Natarajan L, DeMichele A & Steiner AZ 2013 Impact of breast cancer on anti-Müllerian hormone levels in young women. Breast Cancer Research and Treatment 137 571-577. (doi:10.1007/s10549-012-2361-5)
77. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S et al. 2013 Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science Translational Medicine 5 172ra21. (doi:10.1126/scitranslmed.3004925)
78. Turner NH, Partridge A, Sanna G, Di Leo A & Biganzoli L 2013 Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Annals of Oncology 24 2224-2235. (doi:10.1093/annonc/mdt196)
79. te Velde ER & Pearson PL 2002 The variability of female reproductive ageing. Human Reproduction Update 8 141-154. (doi:10.1093/humupd/8.2.141)
80. Wallace WH, Anderson RA & Irvine DS 2005 Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncology 6 209-218. (doi:10.1016/S1470-2045(05)70092-9)
81. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC & Themmen AP 2004 Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Molecular Human Reproduction 10 77-83. (doi:10.1093/molehr/gah015)
82. Yu B, Douglas RA, Ferin DL, Nakhuda GS, Crew K, Lobo RA & Hershman DL 2010 Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116 2099-2105. (doi:10.1002/cncr.25037)